RxDoctor Payments Data

Madeline Rodecker

Family · New Castle, PANPI 1255068458

Payments from drug & device makers

$1,921in general payments, 2019–2025

Across 131 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$527
  • Amgen$365
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$343
  • AstraZeneca$265
  • Pfizer$115
  • Boehringer Ingelheim$97
  • plus $209 from 5 others

What the payments were for

  • Food & beverage$1,921100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,921 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,829
Medicare patients
169
Services billed
259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban474$434,445
XareltoRivaroxaban243$254,984
EntrestoSacubitril/Valsartan107$110,982
Repatha SureclickEvolocumab89$52,768
JardianceEmpagliflozin37$37,595
Repatha PushtronexEvolocumab25$14,506
BrilintaTicagrelor14$10,479
Metoprolol Succinate642$9,450
FarxigaDapagliflozin Propanediol14$8,307
Potassium Chloride219$5,139
Ranolazine ErRanolazine52$4,644
Atorvastatin Calcium390$4,049
Rosuvastatin Calcium258$3,876
Midodrine Hcl18$3,779
Diltiazem 24hr Er (Cd)Diltiazem Hcl90$2,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$115$434,445474 claims
Johnson & JohnsonXarelto$527$254,984243 claims
NovartisEntresto$96$110,982107 claims
Boehringer IngelheimJardiance$97$37,59537 claims
AstraZenecaBrilinta, Farxiga$265$18,78528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.

Other family in New Castle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →